WO2015018471A1 - Pni (substance psycho-neuro-immunologique) de protection des cellules lobbyistes - Google Patents

Pni (substance psycho-neuro-immunologique) de protection des cellules lobbyistes Download PDF

Info

Publication number
WO2015018471A1
WO2015018471A1 PCT/EP2014/001769 EP2014001769W WO2015018471A1 WO 2015018471 A1 WO2015018471 A1 WO 2015018471A1 EP 2014001769 W EP2014001769 W EP 2014001769W WO 2015018471 A1 WO2015018471 A1 WO 2015018471A1
Authority
WO
WIPO (PCT)
Prior art keywords
root
pni
psychoneuroimmunium
herb
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/001769
Other languages
German (de)
English (en)
Inventor
Ernst Fekete
Karin Hübner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015018471A1 publication Critical patent/WO2015018471A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the use of pure "PNI", cell protection of a physiologically acceptable purely natural active ingredient, a herbal preparation for the manufacture of a medicament for the treatment of internal and external cancer and non-inflammatory rheumatic diseases and diabetes.
  • the medical device can be used as:
  • immune regulation is activated via the stress axis
  • the present invention is a synergistic combination of exclusively natural active ingredients for supporting and dynamizing the "stress axis" from the microorganisms of the intestine to the adrenal cortex to the pituitary gland.
  • stress axis describes the communication between the intestinal bacterial system and the brain via nerve cells of the intestinal wall (enteric nervous system), biochemical messengers, the adrenal cortex, the blood and neuronal bandages.
  • the adaptive antigen-presenting cells of the white blood cells (T and B lymphocytes, monocytes, macrophages) play an important role as mediators, as well as the dendritic cells, whose extensions can be found on the skin, mucosa and lymphatic tissue.
  • T and B lymphocytes, monocytes, macrophages play an important role as mediators, as well as the dendritic cells, whose extensions can be found on the skin, mucosa and lymphatic tissue.
  • it deals with the recording and processing of externally recorded, on the other organic and psychic signals; the communication of organs and regulatory circuits and, above all, meaningful and efficient countermeasures of a body that has to deal with infections, parasites and / or cancerous tumors.
  • the present invention of Psychoneuroimmunium is surpassed by any drug, no vitamin and no single therapeutic measure that allows even approximately affecting the learning success towards intestinal and stomach bacteria, immune system and brain.
  • the vibrational and informative power of the microorganisms of the microorganisms play an equally important role here Intestine (which is absorbed and transmitted by the enteric nervous system) as well as the energy transfer via the so-called “stress axis" from the intestinal wall via the organs to the adrenals, from there to the brain.
  • the "PNI” thus acts as a kind of control center for the control and control of the cell activity.Not forget the effect of the "PNI” the functionality of the blood, whose information, cleaning and nutrient power depends on many factors and also about it can be influenced very well by vital substances.
  • the ability of the organism with its immune system to defend against the establishment of growing cancer cell colonies largely depends on the functioning of the circuits just mentioned. Of particular note is the ability of the brain to activate, direct and control natural killer cells, T and B lymphocytes, monocytes and macrophages via nerve signals.
  • the "PNI" can supplement one of the biggest bottlenecks in medicine.
  • the Healing traditions of Medicine, TCM and INDM have been designed to support the overall organic learning and counter-regulation of a living system, such as human beings (or animals, for example), who are in stress and seeking ways, to reorganize and adjust at both the organ and information levels in order to create longer term wellbeing.
  • the term is apt when it is said that "PNI" has identified a lobbyist that reunites the fully available mechanisms and regulatory circuits of the autonomic and central nervous systems.
  • PNI palindromic nucleus
  • Processes in living systems can reflect bodily processes and mental reactions the physical. They can be replaced by alternating or running at the same time, which promotes irritation with concomitant weakening of the immune system. This has a massive impact on the desired healing success. It is precisely the balance and balance between the physicality and the mind of the human being that is to be regulated by "PNI" and, through its mode of action, regain the upper hand in order to restore order in the human body for recovery.
  • the present invention of "PNI” breaks this cycle and regulates it, on the other hand parasites, infections and tumor cells are uncovered by the plant agents used in the "PNI” by the body's own energetic charging processes, which can only be proven in the defective cell What strengthens the present medical device "PNI” in its mode of action.As known, cancer patients are not feverish, are included in the "PNI” agents that can retrieve this program mentioned above.
  • the artificial overheating causes a number of other mechanisms, each directly or indirectly harmful to the tumor tissue.
  • the capillary vessels in the tumor tissue usually have no muscle layer and are therefore not able to expand in the fever-like overheating, in contrast to the microvessels in adjacent healthy tissue.
  • the heat generated by the energetic program of the "PNI” remains due to the resulting reduced blood flow substantially in the tumor tissue and thus causes a selective increase in tumor temperature.
  • This caused by the "PNI” in the natural way "heat trap” thus leads to an oxygen deficiency and a nutrient depletion in the tumor, which leads to a disruption of important metabolic processes in cell division and Zellerigen.
  • Acidosis (acid) of carcinogenic cells
  • Acidosis of carcinogenic cells is a metabolic rate increased by the formation of heat. These and the resulting oxygen deficit (hypoxia) force the tumor cell to anaerobic energy production. The tumor cell now gains its energy, e.g. by converting the sugar from the intracellular space. This transformation produces lactate and thus increasingly an acidic cell milieu, which leads to a malfunction in the cell and due to the simultaneously disturbed repair mechanisms to the death of the diseased cells (apoptosis) by acidosis.
  • the fever-like situation causes a constant damage of the lipid bilayer of the tumor cells and thus an altered lipid-protein interaction. This can result in denaturing of the cellular proteins and significantly disrupt the cell's ability to divide.
  • the medical device psychoneuroimmunium can be said to deprive the tumor cell of any opportunity to obtain nutrients or tap into such sources, and the tumor is starving, noting that cancer avoids a starving system and thus eliminates itself.
  • PNI Quality of life of humans in their worst crisis
  • the active substance Psychoneuroimmunium contains the following ingredients: Stock List Herbs:
  • the herb and root powder mixture also contains, in purely natural form, further below-mentioned modes of action, which are coordinated with one another according to their purpose: Angelica root, Stinging nettle, Valerian herb, Ceylon green OP, Chelidonium, Carduus marianus, Eberraut herb, Echtas lab herb, Fennel, Ginko, Goldenrod herb, Cloves, Elderflower, Oat green, Ginger, Lapacho bark, Calamus root, Nasturtium, Corn hair, Lab herb, Milk thistle herb, Melissa leaves, Mistletoe , Horseradish root, passion flower, Pommera peel bitter, butterbur, yarrow, licorice root, rose root, rose petals, iris root, pansy blue-flowering, taiga root, devil's claw, juniper
  • the other active ingredients are: bearded helmet herb, Oldenlandiakraut, Chinese cinnamon bark / cassia, red radish sage root, citrus root, chines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne l'utilisation de "PNI" pure, protection cellulaire d'une substance active purement naturelle et physiologiquement acceptable, d'une préparation végétale pour préparer un médicament à usage interne et externe destiné au traitement de pathologies cellulaires et cancéreuses. Cette substance active "PNI" est une combinaison synergique de substances actives exclusivement naturelles servant à soutenir et dynamiser l'axe de stress. Les substances actives font fonctionner une communication entre le système des bactéries intestinales et le cerveau par le biais de cellules nerveuses de la paroi intestinale (système nerveux entérique), de substances messagères biochimiques, du cortex surrénal, du sang et par le biais de connexions neuronales afin d'obtenir l'effet curatif.
PCT/EP2014/001769 2013-08-05 2014-06-27 Pni (substance psycho-neuro-immunologique) de protection des cellules lobbyistes Ceased WO2015018471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102013013029.8A DE102013013029A1 (de) 2013-08-05 2013-08-05 Lobbyist-Zellschutz PNI (Psychoneuroimmunium)
DE102013013029.8 2013-08-05

Publications (1)

Publication Number Publication Date
WO2015018471A1 true WO2015018471A1 (fr) 2015-02-12

Family

ID=51211169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/001769 Ceased WO2015018471A1 (fr) 2013-08-05 2014-06-27 Pni (substance psycho-neuro-immunologique) de protection des cellules lobbyistes

Country Status (2)

Country Link
DE (1) DE102013013029A1 (fr)
WO (1) WO2015018471A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020141083A1 (fr) * 2018-12-31 2020-07-09 Max Zeller Soehne Ag Combinaison d'extraits de cimicifuga et de petasites pour le traitement thérapeutique ou prophylactique du cancer
CN114304609A (zh) * 2021-12-17 2022-04-12 广州市沐家健康产业有限公司 一种具有降脂功效的玫瑰花酵素及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190137909A (ko) * 2017-04-22 2019-12-11 차이동 친 세포 해당과 글루타민 대사과정 동시 억제방법 및 응용

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089542A2 (fr) * 2000-05-25 2001-11-29 Pharmaton S.A. Methode destinee a ameliorer la protection cellulaire
WO2004105777A1 (fr) * 2003-05-22 2004-12-09 Bauer, Wulf Pierre pulverisee, en particulier medicament a base de poudre de dolomie, pour traiter des pathologies cancereuses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089542A2 (fr) * 2000-05-25 2001-11-29 Pharmaton S.A. Methode destinee a ameliorer la protection cellulaire
WO2004105777A1 (fr) * 2003-05-22 2004-12-09 Bauer, Wulf Pierre pulverisee, en particulier medicament a base de poudre de dolomie, pour traiter des pathologies cancereuses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N.N.: "PNI: Beschreibung Zusammensetzung", 7 November 2011 (2011-11-07), XP055134793, Retrieved from the Internet <URL:http://www.dein-spieglein.de/joomla/index.php?option=com_fireboard&Itemid=77&id=18&catid=14&func=fb_pdf> [retrieved on 20140814] *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020141083A1 (fr) * 2018-12-31 2020-07-09 Max Zeller Soehne Ag Combinaison d'extraits de cimicifuga et de petasites pour le traitement thérapeutique ou prophylactique du cancer
CN114304609A (zh) * 2021-12-17 2022-04-12 广州市沐家健康产业有限公司 一种具有降脂功效的玫瑰花酵素及其制备方法
CN114304609B (zh) * 2021-12-17 2022-10-11 广州市巴菲巴健康产业有限公司 一种具有降脂功效的玫瑰花酵素及其制备方法

Also Published As

Publication number Publication date
DE102013013029A1 (de) 2015-02-05

Similar Documents

Publication Publication Date Title
Shalini et al. Neuroprotection with Bacopa monnieri–a review of experimental evidence
Abu-Seida Effect of propolis on experimental cutaneous wound healing in dogs
CN104367765A (zh) 一种用于治疗抑郁症的中药组合物及其制备方法和应用
DE69209414T2 (de) Hirnaktivitätfördernde Zubereitungen
Thorat et al. Brahmi-The memory booster medicinal herb
CN105920476A (zh) 防治阿尔茨海默病中药组合物及其制备方法
WO2015018471A1 (fr) Pni (substance psycho-neuro-immunologique) de protection des cellules lobbyistes
Yusuf et al. A histological study on the effect of aqueous extract of cactus on frontal cortex of diabetes mellitus Wistar rat
DE60124516T2 (de) Kombination des lezithins mit ascorbinsäure
WO2019038776A1 (fr) Composition médicinale pour le traitement de problèmes d&#39;acidité et d&#39;indigestion
Tsyvunin et al. Antiepileptic potential of Fumaria schleicheri and Ocimum basilicum dry extracts
Iermolenko et al. Theoretical justification of the search for potential medicinal products containing food plant biologically active substances
DE202013007044U1 (de) Lobbyist-Zellschutz PNI (Psychoneuroimmunium)
KR102634246B1 (ko) 벌사상자 추출물을 포함하는 인지 기능 장애 또는 신경 염증의 예방 또는 치료용 조성물
Otimenyin et al. Hypnotic effect of methanolic extracts of Annona senegalensis bark and Ficus thonningii leaves in mice and chicks
Mindell Dr. Earl Mindell's Herb Bible: Fight Depression and Anxiety, Improve Your Sex Life, Prevent Illness, and Heal Faster—the All-Natural Way
CN104069062B (zh) 一种防治缺血性心脑血管疾病的豆腐果苷注射剂及其制备方法与应用
CN107441105B (zh) 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用
Adeyemi et al. The effect of tardalafil on the aphrodisiac properties of Allium sativum and Allium cepa using behavioural models in rats
CN103908596B (zh) 一种治疗癫痫的中药
Akram et al. Peppermint in medicine: Pharmacological insights and clinical relevance
RU2077888C1 (ru) Способ лечения лучевой болезни у животных
CN110772580A (zh) 一种调节睡眠的组合物、复方精油及其应用
Jaryal et al. Herbal honey, uses, and future perspectives
DE102015016162A1 (de) Nahrungsergänzungsmittel zur Unterstützung bei Krebserkrankungen, Infekten und Parasiten (NIA)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14741199

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 14741199

Country of ref document: EP

Kind code of ref document: A1